161 results
Page 3 of 9
6-K
EX-99.1
zyhuohmc1mejwc
7 Feb 22
Current report (foreign)
2:40pm
6-K
EX-99.1
xu9c8kppkg8nvfnxy
19 Jan 22
Jyseleca®▼ (Filgotinib) Licensed for the Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis In Great Britain
11:37am
6-K
EX-99.1
2r69ci
17 Nov 21
Jyseleca®▼(filgotinib) approved in the European Union for the treatment of ulcerative colitis
6:00am
6-K
EX-99.2
h7a719n5i mw3x
8 Nov 21
Galapagos reports commercial and operational progress at Q3 financial results
4:03pm
S-8
EX-99.1
al5ap8n
26 Oct 21
Registration of securities for employees
4:07pm
S-8
EX-99.2
rgfsgh 8p
26 Oct 21
Registration of securities for employees
4:07pm
S-8
EX-4.1
hsf5dqqk18iy0d2y
26 Oct 21
Registration of securities for employees
4:07pm
S-8
EX-99.3
k8tvhl 1z4rufkp
26 Oct 21
Registration of securities for employees
4:07pm
6-K
EX-99.1
h8d4b
6 Oct 21
Galapagos presents new data from the SELECTION Phase 3 program at the United European Gastroenterology Week (UEGW) 2021 congress
6:00am
6-K
EX-99.1
zzm e4x2w
6 Oct 21
Galapagos announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohn’s Disease
6:00am
6-K
EX-99.1
akt344tyt7l7i2uv5i
20 Sep 21
Current report (foreign)
9:26am
6-K
EX-99.2
myn456n 8w1t7q
5 Aug 21
Galapagos reports H1 financial results with refocused pipeline and operational progress
4:02pm
6-K
EX-99.1
b0cvfxgg
12 Jul 21
New post-hoc analyses of data from SELECTION Phase 3 program presented at European Crohn’s and Colitis Organisation (ECCO) virtual congress
9:02am